照射野大小对接受实体瘤放疗患者治疗所致淋巴细胞减少风险及严重程度的影响
本文回顾实体瘤放疗中放射性淋巴细胞减少(RIL)的临床意义与剂量学预测因素。严重RIL与胶质瘤、肺癌和胰腺癌生存较差相关,RIL风险与照射野大小、分次剂量和分次数相关,SBRT和质子治疗与较低RIL风险相关。作者认为免疫系统应视为危及器官,绝对淋巴细胞计数是放疗免疫毒性的重要生物标志物,需进一步研究。
要点
- 严重RIL与胶质瘤、肺癌和胰腺癌生存较差相关。
- RIL风险与照射野大小、分次剂量及分次数相关。
- SBRT和质子治疗与较低RIL风险相关。
核心结论
- 放疗期间应将免疫系统视为危及器官,绝对淋巴细胞计数是放疗所致免疫毒性的重要生物标志物。
- 放疗剂量和技术影响RIL风险及严重程度。
- 需进一步研究以准确描述放疗所致免疫毒性并制定预防或减轻这一临床显著副作用的策略。
研究设计与样本
- 本文为综述,回顾关于放疗所致免疫系统毒性临床意义及剂量学预测因素的现有文献。
主要发现
- 严重RIL与胶质瘤、肺癌和胰腺癌等多种实体瘤的较差生存相关。
- RIL风险与照射野大小、分次剂量和分次数相关。
- SBRT和质子治疗技术与较低RIL风险相关。
局限性
- 需进一步研究以准确描述放疗所致免疫毒性并制定预防或减轻这一临床显著副作用的策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Radiation-induced lymphopenia (RIL) is the result of direct toxicity to circulating lymphocytes as they traverse the irradiated field, occurs in 40% to 70% of patients who undergo conventional external beam radiation therapy, and is associated with worse outcomes in multiple solid tumors. As immunotherapy strategies evolve, a better understanding of radiation's effects on the immune system is needed in order to develop rational methods of combining RT with immunotherapy. METHODS AND MATERIALS: This paper is a review of the available literature on the clinical significance and dosimetric predictors of radiation-induced toxicity to the immune system. RESULTS: An association between severe RIL and inferior survival has been described in multiple solid tumors, including glioma, lung cancer, and pancreatic cancer. RIL risk is correlated with field size, dose per fraction, and fraction number. SBRT and proton therapy techniques are associated with lower RIL risk. CONCLUSIONS: The immune system should be considered an organ at risk during RT, and absolute lymphocyte count is an important biomarker of RT-induced immunotoxicity. Radiation dose and technique affect the risk and severity of RIL. Further research is needed to accurately characterize RT-induced immunotoxicity and develop strategies to prevent or mitigate this clinically significant side effect.
引用
- Ellsworth SG. Field size effects on the risk and severity of treatment-induced lymphopenia in patients undergoing radiation therapy for solid tumors. Adv Radiat Oncol. 2018. PMID: 30370350. doi:10.1016/j.adro.2018.08.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。